Sign Up Today and Learn More About Frequency Therapeutics Stock
Invest in or calculate the value of your shares in Frequency Therapeutics or other pre-IPO companies through EquityZen's platform.
Frequency Therapeutics Stock
Small, molecular progenitor cells drugs
About Frequency Therapeutics Stock
Founded
2015
Headquarters
Woburn, MA, US
Total Funding
76.0M
Industries
Science and Engineering, Health Care, Biotechnology
Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Through the transitory activation of these progenitor cells, Frequency enables disease modification without the complexity of genetic engineering. The lead program re-creates sensory cells in the inner ear to treat chronic noise induced hearing loss, which affects over 30 million people in the U.S. alone.
Frequency Therapeutics Press Mentions
Stay in the know about the latest news on Frequency Therapeutics
A race is underway to repair our hearing — with medicine
TechCrunch • Jul 28, 2017
Researchers devise method for regenerating hair cells to help reverse hearing loss
TechCrunch • Feb 22, 2017
Frequency Therapeutics Management
Leadership team at Frequency Therapeutics
Co-founder, President and Chief Executive Officer
David L. Lucchino
Co-founder and Vice President, Biology and Regenerative Medicine
Will McLean
Join now and verify your accreditation status to gain access to:
- Frequency Therapeutics Current Valuation
- Frequency Therapeutics Stock Price
- Frequency Therapeutics Management
- Available deals in Frequency Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Frequency Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Frequency Therapeutics Revenue and Financials
- Frequency Therapeutics Highlights
- Frequency Therapeutics Business Model
- Frequency Therapeutics Risk Factors
- Frequency Therapeutics Research Report from SACRA Research
Trading Frequency Therapeutics Stock
How to invest in Frequency Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Frequency Therapeutics through EquityZen funds. These investments are made available by existing Frequency Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Frequency Therapeutics stock?
Shareholders can sell their Frequency Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."